TL;DR: The Centers for Medicare & Medicaid Services modified NCD 311, the National Coverage Determination governing nesiritide (Natrecor®) coverage for heart failure treatment. The CMS nesiritide coverage policy has been non-coverage since March 2, 2006 — this 2026 update reaffirms that position. Here's what billing teams need to know before submitting any claim tied to this drug.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Nesiritide for Treatment of Heart Failure Patients |
| Policy Code | NCD 311 |
| Change Type | Modified |
| Effective Date | 2026-01-09 |
| Impact Level | Medium |
| Specialties Affected | Cardiology, Hospital Medicine, Inpatient Billing, Revenue Cycle |
| Key Action | Flag any nesiritide claims for CHF as non-covered under Medicare; confirm MAC discretion applies before billing off-label use |
CMS Nesiritide Coverage Criteria and Medical Necessity Requirements 2026
The NCD 311 CMS system determination is straightforward — and not in your favor if you're treating congestive heart failure (CHF) patients with nesiritide. The Centers for Medicare & Medicaid Services determined, effective March 2, 2006, that nesiritide for CHF treatment is not reasonable and necessary for Medicare beneficiaries. That determination has not changed. The January 9, 2026 date reflects a modification in CMS's system — it does not alter the clinical or billing rules, which have been in place for nearly 20 years.
There are no nationally covered indications under this coverage policy. None. CMS reviewed the evidence and concluded it does not support medical necessity for nesiritide in any CHF setting — inpatient, outpatient, or otherwise.
Nesiritide carries FDA approval for intravenous treatment of acutely decompensated congestive heart failure in patients with dyspnea at rest or with minimal activity. FDA approval and Medicare medical necessity are two different standards. CMS is not bound to cover a drug just because the FDA approved it — and NCD 311 is a clear example of that distinction in action.
This matters because nesiritide billing under Medicare for CHF is a path to claim denial. If your billing team is processing any nesiritide claims tied to a CHF diagnosis, stop and review before submission.
CMS Nesiritide Exclusions and Non-Covered Indications
The non-coverage here is absolute for CHF — not condition-specific or setting-specific, but drug-plus-indication-specific. CMS concluded that nesiritide for the treatment of CHF is not covered in any setting. That covers inpatient hospital services, incident-to services, and any other care context where a Medicare beneficiary is the patient.
This is not a gray area. The policy language says "any setting," and NCD 311 applies nationally. Under general Medicare program principles, MACs cannot override a national non-coverage determination for a specific indication. If a MAC has issued a local coverage determination (LCD) that touches nesiritide, it cannot conflict with NCD 311 on the CHF indication.
There is one carve-out in the policy language, and it requires careful reading. Section D of NCD 311 states that the non-coverage determination applies only to the CHF indication, and that it does not change MAC discretion to cover other off-label uses — or use consistent with the current FDA indication. That last phrase is the ambiguous part. The source language does not clearly establish a separate, billable coverage pathway for the FDA-approved acutely decompensated CHF indication. Do not treat it as one. If you believe this carve-out applies to a claim you're building, go directly to your MAC for written guidance before you bill. This is not a situation where you can infer coverage from the policy text alone.
For off-label uses that are clearly not CHF, MAC discretion applies — but "preserved discretion" is not the same as "automatic coverage." Document the specific indication being treated, and confirm your MAC's local policy before submitting.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Nesiritide for CHF treatment — any setting | Not Covered | No specific codes listed in NCD 311 | Effective March 2, 2006. Applies to all Medicare beneficiaries in all settings. |
| Nesiritide for off-label uses other than CHF | MAC Discretion | No specific codes listed in NCD 311 | MACs retain discretion to cover off-label uses not addressed by NCD 311. Verify with your specific MAC before billing. |
| Nesiritide consistent with FDA indication (acutely decompensated CHF with dyspnea) | Ambiguous — MAC Guidance Required | No specific codes listed in NCD 311 | Section D language is unclear on whether this creates a separate covered pathway. Do not bill this as covered without direct written confirmation from your MAC. |
CMS Nesiritide Billing Guidelines and Action Items 2026
The January 9, 2026 modification date is your trigger for audit and process review — not because the coverage rules changed, but because this update is a reminder to verify your current billing practices against a non-coverage determination that has been in place since 2006.
| # | Action Item |
|---|---|
| 1 | Pull any open or pending nesiritide claims tied to a CHF diagnosis. Review them before submission. Any claim with a primary or secondary CHF diagnosis code and a nesiritide drug administration line is a claim denial risk under NCD 311. Do not submit without compliance review. |
| 2 | Update your charge capture workflow to flag nesiritide drug administration when CHF codes are present. Your billing system should surface a coverage warning anytime a nesiritide administration charge appears alongside a CHF diagnosis. This is a process change, not a one-time audit. |
| 3 | Contact your Medicare Administrative Contractor before billing any off-label nesiritide use. NCD 311 preserves MAC discretion for non-CHF indications — but preserved discretion is not automatic coverage. Check your MAC's LCD database and document their response in writing. |
| 4 | Train your cardiology and hospital medicine coders on the CHF vs. non-CHF distinction. The NCD's carve-out for off-label use is only useful if your team codes the indication correctly. A coder who defaults to a CHF diagnosis when the clinical picture is more nuanced will generate a denied claim. The clinical documentation and the diagnosis code must match the actual indication being billed. |
| 5 | Review your facility's nesiritide billing practices for CHF admissions. NCD 311 covers benefit categories including inpatient hospital services and incident-to services. Coverage is denied under NCD 311 for CHF indications regardless of care setting. Talk to your MAC for specific guidance on how to handle billing mechanics for denied nesiritide claims in your context. |
| 6 | If your facility has active nesiritide use in a CHF population, loop in your compliance officer. NCD 311 has been in effect since 2006. A compliance review of your nesiritide billing history is a reasonable precaution — talk to your compliance officer about whether that review is warranted given your specific situation. That determination is theirs to make, not ours. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Nesiritide Under NCD 311
A Note on Codes
The policy data for NCD 311 does not list specific CPT, HCPCS, or ICD-10 codes. This is not unusual for drug-specific NCDs that address coverage by indication rather than by procedure code. The non-coverage determination applies to the drug-plus-indication combination, not to a specific billing code.
NCD 311 does not enumerate billing codes for nesiritide administration. Work directly with your MAC and your internal coding resources to confirm which codes apply to your specific clinical scenario. This is especially true for off-label or non-CHF situations where MAC discretion applies.
Do not assume that the absence of a code list in the NCD means the claim is unaffected. The non-coverage determination is broad and applies regardless of which administration code you use to bill the drug.
What to Document When Billing Off-Label Use
Because the NCD 311 carve-out for off-label and non-CHF indications relies on MAC discretion, your documentation needs to carry the weight. At minimum, make sure your records include:
- The specific indication being treated (not CHF)
- Clinical rationale for nesiritide over alternatives
- Reference to any applicable MAC LCD or guidance
- Physician attestation of medical necessity for the specific non-CHF use
This documentation is your defense if a claim is questioned. Medicare medical necessity reviews will start with the diagnosis code and the clinical notes — make sure both tell the same story.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.